ClinicalTrials.Veeva

Menu
N

New Hope Clinical Research | Charlotte, NC

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Rapastinel
SEP-363856
Brexpiprazole
Aticaprant
Cariprazine
SEP-4199
Troriluzole
Azetukalner
T3D-959
SP-624

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

8 of 49 total trials

A Study to Assess the Efficacy and Safety of ITI-1284 in the Treatment of Psychosis Associated With Alzheimer's Disease

This is a multicenter, randomized, double-blind, parallel-group, placebo-controlled, flexible-dose study evaluating the efficacy, safety, and tolerab...

Enrolling
Alzheimer Disease
Psychotic Disorders
Drug: Placebo
Drug: ITI-1284

This is a global, phase 3, randomized, double-blind, parallel-group, 3-arm, placebo-controlled, multicenter study designed to compare the efficacy, s...

Enrolling
Generalized Anxiety Disorder
Drug: SEP-363856
Other: Placebo

X-NOVA-OLE is a multicenter, open-label study to evaluate the long-term safety, tolerability, and efficacy of azetukalner as a monotherapy in adult p...

Active, not recruiting
Major Depressive Disorder
Drug: Azetukalner

This study will evaluate the efficacy and safety of SPN-821 in adults with major depressive disorder

Enrolling
Major Depressive Disorder (MDD)
Drug: Placebo
Drug: SPN-821 2400 mg

The purpose of this study is to test the safety and efficacy of BHV-3000 versus placebo in the acute treatment of moderate or severe migraine in chil...

Enrolling
Pediatric Migraine
Drug: Rimegepant/BHV3000
Drug: Matching placebo

The reason for this trial is to see if the investigational product, called RGH-202, is safe and well tolerated, and can help people with social anxie...

Not yet enrolling
Social Anxiety Disorder
Drug: RGH-202
Drug: Placebo

Bipolar disorder is a severe chronic mood disorder that affects up to 4% of the adult population in the United States. The purpose of this study is t...

Active, not recruiting
Bipolar I or II Disorder
Drug: ABBV-932

This is a study to evaluate the efficacy, safety, and tolerability of BMS-986368, a FAAH/MAGL inhibitor, for the treatment of agitation in participan...

Enrolling
Alzheimer Disease
Agitation
Drug: Placebo
Drug: BMS-986368

Trial sponsors

Otsuka logo
Allergan logo
AbbVie logo
Janssen (J&J Innovative Medicine) logo
Biohaven logo
Indivior logo
Merck Sharp & Dohme (MSD) logo
Novo Nordisk logo
S
Sumitomo Pharma logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2026 Veeva Systems